- Home
- ROMA vs PRLD Comparison
ROMA vs PRLD Comparison
Compare ROMA & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ROMA | PRLD |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 542.0M | 529.1M |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ROMA | PRLD |
|---|---|---|
| Price | $9.24 | $4.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.67 |
| AVG Volume (30 Days) | 2.3K | ★ 505.7K |
| Earning Date | 12-23-2025 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,140,000.00 |
| Revenue This Year | N/A | $320.10 |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 73.43 |
| 52 Week Low | $1.16 | $0.98 |
| 52 Week High | $11.77 | $6.83 |
Technical Indicators
Market Signals| Indicator | ROMA | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 56.10 | 35.24 |
| Support Level | $8.01 | $3.92 |
| Resistance Level | $9.75 | $5.42 |
| Average True Range (ATR) | 0.35 | 0.38 |
| MACD | 0.06 | -0.18 |
| Stochastic Oscillator | 78.95 | 2.26 |
Price Performance
Historical ComparisonAbout ROMA Roma Green Finance Limited
Roma Green Finance Ltd is a professional specialist in the provision of environmental, social and governance (ESG), sustainability and climate change related advisory services through its operating subsidiaries in Hong Kong and Singapore. Its services include Sustainability Program Development, ESG Reporting, Corporate Governance and Risk Management, Climate Change Strategies and Solutions, Environmental Audit, ESG Rating Support and Shareholder Communication, and Education and Training. It operates in one reporting business segment in Hong Kong and Singapore, of which the majority of revenue is derived from Hong Kong.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.